VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

BACKGROUND: The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In this study, VeriStrat was evaluated a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C, Smit, E F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505013/
https://www.ncbi.nlm.nih.gov/pubmed/23079575
http://dx.doi.org/10.1038/bjc.2012.470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505013/
https://www.ncbi.nlm.nih.gov/pubmed/23079575
http://dx.doi.org/10.1038/bjc.2012.470

Ejemplares similares